Bulletin
Investor Alert

Market Pulse Archives

April 10, 2020, 6:25 p.m. EDT · CORRECTED

FDA grants emergency authorization to two blood purification systems

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Terumo Corp. (4543)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

A previous version of this report inaccurately referred to Marker Therapeutics AG, a Swiss biotechnology firm, as Marker Therapeutics Inc., a Houston-based company. The article has been corrected.

The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. /zigman2/quotes/201738044/delayed JP:4543 +1.76% and Marker Therapeutics AG in response to the COVID-19 pandemic. Terumo is a Japanese medical device maker. Marker, a Swiss biotech, is a subsidiary of Marker AG. An EUA does not mean that that the device has been approved by the FDA; it is an authorization granted during an emergency when there are no other treatment options available. The regulator said that the devices can be used for adult patients with COVID-19 who are being cared for in the intensive care unit and have confirmed or imminent respiratory failure to reduce the amount of cytokines in those patients. Some severely ill COVID-19 patients have had "cytokine storms" that can lead to organ failure and death. Year-to-date, Terumo's stock is down 3.9%. The S&P 500 /zigman2/quotes/210599714/realtime SPX +1.23% has dropped 13.6% since the beginning of 2020.

/zigman2/quotes/201738044/delayed
JP : Japan: Tokyo
¥ 4,058.00
+70.00 +1.76%
Volume: 1.27M
May 27, 2020 1:12p
P/E Ratio
36.03
Dividend Yield
0.69%
Market Cap
¥2915.10 billion
Rev. per Employee
¥25.21M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
2,991.77
+36.32 +1.23%
Volume: 3.36B
May 26, 2020 5:20p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.